All In Biotech

Drug Trial Radar · NCT06318884

A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma

A Phase Ia/Ib Dose-escalation and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SCTB35 in Patients With CD20+ Relapse/Refractory B-cell Non-Hodgkin Lymphoma

Last checked: Nov 19, 2026Latest source record: Mar 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

76

Planned (sponsor's estimate)

Start

Apr 2024

Primary completion

Oct 2026

Study completion Dec 2027

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
Mar 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I clinical study designed to evaluate the safety, tolerability, and pharmacokinetics, and preliminary efficacy of SCTB35 monotherapy, an bispecific antibody, in patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma.

Conditions

  • Non-Hodgkin Lymphoma, B-cell

Interventions

  • SCTB35 injectionDrug

    SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and another appropriate dose of SCTB35 will be applied for the dose-expansion cohorts.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-escalation part: dose limited toxicity (DLT)Time frame: During the first cycle (21 days)
  2. Dose-escalation part: incidence rate of adverse event (AE)Time frame: From first dose until 28 days after last dose of study drug or until study completion or participant withdrawal (up to 3 years)
  3. Dose-expansion part: objective response rate (ORR)Time frame: From first dose until up to 2 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.